OverviewSuggest Edit
BioNTech is a biopharmaceutical company developing therapies against cancer and infectious diseases. It provides peptide manufacturing services, GMP (good manufacturing practice) manufacturing services for mRNA and cell and gene therapies, and research services. The company also develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products through selected partners. BioNTech covers a range of platforms, including mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators.
| Type | Public | |
| Founded | 2008 | |
| HQ | Mainz, DE | Map |
| Website | biontech.de | |
| Employee Ratings | More |
Recent NewsAll News
- Worldwide mRNA Vaccines and Therapeutics Industry to 2031 - Featuring Arcturus Therapeutics Holdings, BioNTech and CureVac Among Others
- Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
- BioNTech says COVID-19 vaccine likely to be effective against Indian coronavirus variant
- BioNTech Publishes First Sustainability Report and Receives “Prime” Rating by ISS ESG
Key People/Management at BioNTech
Sean Marett
Chief Business and Chief Commercial Officer
Ugur Sahin
Chief Executive Officer
Sierk Poetting
Chief Financial Officer and Chief Operating Officer
Ryan Richardson
Chief Strategy Officer
Ozlem Tureci
Chief Medical Officer
Richard Gaynor
President of BioNTech US and Chief of R&D
BioNTech Office Locations
BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations
Mainz, DE (HQ)
An der Goldgrube 12
Halle (Saale), DE
Weinbergweg 23
Idar-Oberstein, DE
Vollmersbachstraße 66
Marburg, DE
Emil-von-Behring-Straße 76
Neuried, DE
Forstenrieder Str. 8
Planegg, DE
Am Klopferspitz 19a
BioNTech Financials and Metrics
BioNTech Revenue
BioNTech's revenue was reported to be €1.99 m in FY, 2019
| EUR | |
|---|---|
Net income (FY, 2020) | 15.2m |
EBIT (FY, 2020) | (82.4m) |
Market capitalization (4-Jun-2021) | 45.0b |
Closing stock price (4-Jun-2021) | 189.9 |
Cash (31-Dec-2020) | 1.2b |
EV | 44.1b |
BioNTech's current market capitalization is €45 b.
Annual
| EUR | FY, 2017 |
|---|---|
Debt/Equity | -1.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | -7.8 x |
BioNTech Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Apta IT | ||
| BioNTech Austria Beteiligungen GmbH | ||
| BioNTech Business Services | ||
| BioNTech Cell & Gene Therapies | ||
| BioNTech Diagnostics | ||
| BioNTech Innovative Manufacturing Services | ||
| BioNTech Protein Therapeutics | ||
| BioNTech Real Estate GmbH & Co. KG | ||
| BioNTech Real Estate Verwaltungs | ||
| BioNTech Research and Development |
BioNTech Revenue Breakdown
BioNTech revenue breakdown by business segment: 20.2% from Other Sales Transactions and 79.8% from Collaboration Revenue
BioNTech Cybersecurity Score
BioNTech Online and Social Media Presence
57.2k Twitter followers
BioNTech has 57.2k Twitter Followers. The number of followers has increased 2.6% month over month and increased 38.4% quarter over quarter
BioNTech's Trends
Twitter Engagement Stats for @BioNTech_Group
140
Tweets
169
Following
57.2k
Followers
13
Tweets last 30 days
166
Avg. likes per Tweet
100%
Tweets with engagement
BioNTech News and Updates
June 01, 2021
Worldwide mRNA Vaccines and Therapeutics Industry to 2031 - Featuring Arcturus Therapeutics Holdings, BioNTech and CureVac Among Others
DUBLIN, June 1, 2021 /PRNewswire/ -- The "Global mRNA Vaccines and Therapeutics Market: Focus on Application, mRNA Type, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering. The publisher's...
May 28, 2021
Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
NEW YORK and MAINZ, GERMANY, May 28, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Conditional Marketing Authorization (CMA) for COMIRNATY® in the European Union (EU) has been expanded to include individuals 12 to 15 years of age. This follows the European Me…
May 21, 2021
BioNTech says COVID-19 vaccine likely to be effective against Indian coronavirus variant
BioNTech's chief executive has said that the COVID-19 vaccine it developed with U.S. pharmaceutical group Pfizer is likely to be effective against the Indian variant of coronavirus. The German biotechnology company's CEO, Ugur Sahin, said on Thursday in a meeting with the Turkish health minister t…
May 21, 2021
BioNTech Publishes First Sustainability Report and Receives “Prime” Rating by ISS ESG
MAINZ, Germany, May 21, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, has published its first Sustainability Report. The report focuses on the Company’s commitment to making an im…
May 20, 2021
UPDATE: Pfizer and BioNTech to supply EU with up to 1.8 billion additional COVID vaccine doses
Pfizer Inc. and German partner BioNTech SE said Thursday they have reached a new agreement with the European Commission to supply up to 1.8 billion additional doses of their COVID-19 vaccine. The partners said the agreement is to provide 900 million doses initially with an option for the EC to req…
May 20, 2021
Pfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY®
NEW YORK AND MAINZ, GERMANY, May 20, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companies’ COVID-19 vaccine, to the European Union (EU), with an option for the EC to re…
BioNTech Blogs
November 29, 2020
HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates
HCP 5 Biontechs Sars-Cov-2 Vaccine Candidates
admin
Sun, 11/29/2020 - 20:09
November 29, 2020
HCP 3 Role of Vaccines in Pandemic
HCP 3 Role of Vaccines in Pandemic
admin
Sun, 11/29/2020 - 20:09
BioNTech Frequently Asked Questions
When was BioNTech founded?
BioNTech was founded in 2008.
Who are BioNTech key executives?
BioNTech's key executives are Sean Marett, Ugur Sahin and Sierk Poetting.
How many employees does BioNTech have?
BioNTech has 1,300 employees.
Who are BioNTech competitors?
Competitors of BioNTech include Ohm Oncology, Kite Pharma and 3sbio.
Where is BioNTech headquarters?
BioNTech headquarters is located at An der Goldgrube 12, Mainz.
Where are BioNTech offices?
BioNTech has offices in Mainz, Halle (Saale), Idar-Oberstein, Marburg and in 4 other locations.
How many offices does BioNTech have?
BioNTech has 8 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies